Healthcare
Live Price
Offline$14.44
+6.57% today
1Y Change
+82.32%
Window
Jun 25, 2025 โ Jun 17, 2026
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Cullinan Management, Inc. (CGEM) is a Healthcare stock with a market cap of $920.00M and listed on NASDAQ. The stock last traded around $14.44 and up 82.3% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -19.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -19.6%, free cash flow -21.0% with operating margin 0.0% and ROIC -58.7%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CGEM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -19.6%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -3.6% over the next 5 trading days and finished higher after 1 of those reports.
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -2.6% | -13.4% | -15.2% |
2026 Mar 10, 2026 | +3.8% | -4.0% | -9.9% | +0.3% |
2025 Nov 6, 2025 | +18.9% | -2.2% | +12.5% | +44.1% |
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CGEM
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CGEM Max Drawdown
-31.06%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Uses the longest available daily history for CGEM and SPY.
Company Overview
Cullinan Management, Inc.
NASDAQ
Cullinan Therapeutics Inc. is an early-stage biopharmaceutical company focused on developing targeted therapies for cancer treatment. The company specializes in a range of innovative approaches including immuno-oncology and precision medicine. Its pipeline encompasses a variety of programs targeting defined mutations and tumor-specific mechanisms, aiming to deliver highly effective therapies with fewer side effects compared to traditional treatments. Cullinan Therapeutics Inc. operates within the biotechnology and healthcare sectors, playing a crucial role in advancing cancer treatment options through its novel and strategic drug development processes. By employing a diversified portfolio of therapeutic assets early in their development, the company seeks to address unmet medical needs across multiple cancer indications. This approach not only exemplifies Cullinan's commitment to innovation but also increases its significance in the market as a contributor to the expanding field of targeted cancer therapies.
Valuation, growth, profitability, and balance sheet signals.
Company announcements and filings-style updates.
Next Step
After the overview, the strongest next step is usually chart context or a tighter compare set.